What we do Amanta Healthcare Ltd is a pharma company specializing in sterile liquid pharmaceuticals including Large and Small Volume Parenterals and medical devices using advanced ABFS and ISBM technologies. |
Founded in 1,994 |
Market share Established niche player with 30+ years legacy, strong presence in India and 21 export countries, focused on sterile liquids market. |
Problem solved Provides safe, sterile intravenous and injectables products critical for hospital use and specialty treatments across multiple therapeutic segments. |
Top clients or who we serve Hospitals, healthcare providers, pharma companies, with B2B and exports to emerging and semi-regulated international markets. |
Key management Chairman Bhavesh Patel (Mechanical Engineer, Finance graduate), supported by a skilled management team with pharma industry expertise. |
Our journey and innovations Incorporated in 1994, expanded capacity through multiple specialized lines; merged MRPL in 2018; introduced new product Linezolid I.V. in 2025; commissioned advanced production technologies. |
Where we operate India (major market) and exports to 21 countries including emerging and semi-regulated markets. |
Top products or what we offer Intravenous fluids, injectables, ophthalmics, respiratory and irrigation solutions in various dosage forms packaged via ABFS and ISBM technologies. |
Top brands SteriPort LVPs - market leader in sterile IV fluids; 47 registered products in 120 countries; key revenue driver with high utilization rates. |
Raw materials needed Polypropylene, LDPE, active pharmaceutical ingredients, specialized closure systems for sterile packaging. |
Raw materials supplier Mainly suppliers from Italy, South Korea, and Thailand supplying polymers and pharma materials. |
Recurring vs cyclical contribution Revenue driven by contract manufacturing and product sales; predominantly recurring with steady hospital demand. |
Our industry position A niche specialist in sterile parenteral segment with strong manufacturing capabilities and growing international footprint. |
Financial highlights FY25 revenue INR 275 Cr, net profit INR 10.5 Cr, EBITDA CAGR ~11.6%, ROE 12.4%, reduced debt-to-equity ratio to 2.08x. |
Geographical revenue split 66% revenue from India, 34% from international markets. |
Order book - |
Whats driving growth Capacity expansion, innovation in formulations, export market growth, operational excellence, and new product launches. |
Our future plans Scaling LVP and SVP capacities, solar power plant setup to reduce costs and improve ESG profile, targeting 20%+ CAGR next 2 years. |
Our green promise Implementing 10.8 MW captive solar plant for renewable energy and cost savings to improve sustainability. |
Our people and values 506 employees plus contract workers; culture values operational discipline and innovation with experienced leadership. |
Key challenges ahead Managing regulatory requirements for global expansion, competitive pricing pressure, raw material sourcing risk. |
Interesting facts First mover in ISBM technology for IV fluids; produces high-utilization SteriPort lines with minimal rejection rates. |
Risks and strategy Mitigates regulatory and market risks by geographic diversification, product innovation, and steady financial deleveraging. |
